肝硬度测量的动态变化可预测晚期慢性肝病的结局
这项回顾性队列研究纳入2508例接受至少2次可靠肝硬度测量(LSM)且间隔至少180天的慢性肝病患者,按基线LSM分层。在代偿性晚期慢性肝病(cACLD)患者中,LSM任何时间点升高20%与肝失代偿和肝病相关死亡风险增加相关,且LSM动态变化预测12个月内肝失代偿的AUC达0.933。
要点
- cACLD患者LSM升高20%与肝失代偿风险增加约50%相关(HR 1.58)。
- LSM动态变化预测12个月内肝失代偿的AUC为0.933,优于FIB-4、MELD和单次LSM。
- cACLD患者LSM降至<20 kPa者肝失代偿风险显著降低(HR 0.13)。
核心结论
- 重复进行LSM可为晚期慢性肝病患者提供个体化的肝失代偿和肝病相关死亡风险更新评估。
研究设计与样本
- 回顾性队列研究,纳入2508例接受2次及以上可靠LSM且间隔至少180天的慢性肝病患者,基线按非晚期慢性肝病(LSM<10 kPa)、代偿性晚期慢性肝病(LSM≥10 kPa)和失代偿性晚期慢性肝病分层。
主要发现
- 共纳入2508例患者,8561次可靠LSM(每例3次,四分位距2-4次):非ACLD 1647例(65.7%),cACLD 757例(30.2%),失代偿性ACLD 104例(4.1%)。
- 中位随访71个月,非ACLD中7例(0.4%)和cACLD中83例(10.9%)发生肝失代偿。
- cACLD患者LSM任何时间点升高20%与肝失代偿风险增加约50%相关(HR 1.58;95%CI 1.41-1.79;P<.001),与肝病相关死亡风险增加相关(HR 1.45;95%CI 1.28-1.68;P<.001)。
- LSM动态变化预测12个月内肝失代偿的AUC为0.933,数值上优于FIB-4动态变化(0.873)、MELD(0.835)和单次LSM(基线LSM 0.846;第二次LSM 0.880)。
- cACLD患者LSM降至<20 kPa者肝失代偿风险显著降低(HR 0.13;95%CI 0.07-0.24)。
关键数值与推荐
- cACLD患者LSM任何时间点升高20%:肝失代偿HR 1.58(95%CI 1.41-1.79;P<.001),肝病相关死亡HR 1.45(95%CI 1.28-1.68;P<.001)。
- LSM动态变化预测12个月内肝失代偿的AUC为0.933。
- cACLD患者LSM降至<20 kPa:肝失代偿HR 0.13(95%CI 0.07-0.24)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Liver stiffness measurements (LSMs) provide an opportunity to monitor liver disease progression and regression noninvasively. We aimed to determine the prognostic relevance of LSM dynamics over time for liver-related events and death in patients with chronic liver disease. METHODS: Patients with chronic liver disease undergoing 2 or more reliable LSMs at least 180 days apart were included in this retrospective cohort study and stratified at baseline (BL) as nonadvanced chronic liver disease (non-ACLD, BL-LSM < 10 kPa), compensated ACLD (cACLD; BL-LSM ≥ 10 kPa), and decompensated ACLD. Data on all consecutive LSMs and clinical outcomes were collected. RESULTS: There were 2508 patients with 8561 reliable LSMs (3 per patient; interquartile range, 2-4) included: 1647 (65.7%) with non-ACLD, 757 (30.2%) with cACLD, and 104 (4.1%) with decompensated ACLD. Seven non-ACLD patients (0.4%) and 83 patients with cACLD (10.9%) developed hepatic decompensation (median follow-up, 71 months). A 20% increase in LSM at any time was associated with an approximately 50% increased risk of hepatic decompensation (hazard ratio, 1.58; 95% CI, 1.41-1.79; P < .001) and liver-related death (hazard ratio, 1.45; 95% CI, 1.28-1.68; P < .001) in patients with cACLD. LSM dynamics yielded a high accuracy to predict hepatic decompensation in the following 12 months (area under the receiver operating characteristics curve = 0.933). The performance of LSM dynamics was numerically better than dynamics in Fibrosis-4 score (0.873), Model for End-Stage Liver Disease (0.835), and single time-point LSM (BL-LSM: 0.846; second LSM: 0.880). Any LSM decrease to <20 kPa identified patients with cACLD with a substantially lower risk of hepatic decompensation (hazard ratio, 0.13; 95% CI, 0.07-0.24). If reliable, LSM also confers prognostic information in decompensated ACLD. CONCLUSIONS: Repeating LSM enables an individual and updated risk assessment for decompensation and liver-related mortality in ACLD.
引用
- Semmler G, Yang Z, Fritz L, et al. Dynamics in Liver Stiffness Measurements Predict Outcomes in Advanced Chronic Liver Disease. Gastroenterology. 2023. PMID: 37442301. doi:10.1053/j.gastro.2023.06.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。